Last reviewed · How we verify
NCT06020287
The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
trial testing the robot-assisted laparoscopic radical prostatectomy in Prostatectomy in 233 participants. Completed in 27 December 2022.
31 May 2022
Quick facts
| Lead sponsor | Nanjing University School of Medicine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 233 |
| Start date | 1 September 2020 |
| Primary completion | 31 May 2022 |
| Estimated completion | 27 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- the robot-assisted laparoscopic radical prostatectomy
Conditions studied
- Prostatectomy — all drugs for Prostatectomy →
- Prostate Neoplasm — all drugs for Prostate Neoplasm →
Sponsor
Nanjing University School of Medicine
Who can join
Eligibility, male only, with Prostatectomy or Prostate Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study was to compare the perioperative outcomes, postoperative urinary control rates and positive surgical margin (PSM) rates of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach (AP-RARP) with the Retzius-sparing approach (RS-RARP) and anterior approach (anterior-RARP) in the treatment of prostate cancer. The main question it aims to answer was: • The early therapeutic efficacy of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach Participants has been underwent: * AP-RARP * RS-RARP * anterior-RARP Researchers compared the three groups to see if AP-RARP combines the advantages of anterior and posterior RARP and is a feasible surgical option for the treatment of prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06020287
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatectomy
Currently open trials in the same condition.
- NCT06274047 — PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life i · Phase 3 · recruiting
- NCT06982469 — High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy · recruiting
- NCT03080116 — Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy · Phase 2 · active not recruiting
Other Nanjing University School of Medicine trials
Trials by the same sponsor.
- NCT06285279 — The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases · Phase 1 · recruiting
- NCT06226896 — Effects of Dapagliflozin on Progression of Alport Syndrome · active not recruiting
- NCT05863936 — Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis · Phase 3 · unknown
- NCT06376214 — Daratumumab for Patients With Light Chain Amyloidosis · NA · recruiting
- NCT04507945 — Stablishment of Prevention and Treatment System for Intestinal Dysfunction · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06020287 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing University School of Medicine
- Last refreshed: 31 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06020287.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing